Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
Fig 3
Scatterplots of bootstrap replications of incremental cost-effectiveness ratios in terms of the number of deaths.
Panel (A): Estimates of incremental cost-effectiveness ratios in terms of death from any cause (for all men in the trial). Panel (B): Estimates of incremental cost-effectiveness ratios in terms of death from prostate cancer (for men diagnosed with prostate cancer). Panel (C): Estimates of incremental cost-effectiveness ratios in terms of death from causes other than prostate cancer (for men diagnosed with prostate cancer).